Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The association between elevated plasma levels of lipoprotein (a) [Lp(a)] and atherosclerotic cardiovascular disease (ASCVD) has been discussed for many years.
|
30847681 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein (a) [Lp(a)] is an independent risk factor for atherosclerosis-related events that is under strong genetic control (heritability = 0.68-0.98).
|
25575512 |
2015 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression.
|
9799211 |
1998 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this review is to highlight our emerging understanding of lipoprotein(a) [Lp(a)]'s role in atherosclerotic cardiovascular disease (ASCVD), its structure-function relationship, and promising developments within the therapeutic pipeline.
|
31261178 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of lipoprotein[a] in atherosclerosis.
|
11122750 |
2000 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
High lipoprotein(a) [Lp(a)] levels are a major risk factor for the development of atherosclerosis.
|
26147378 |
2015 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, elevated Lp(a) levels may either induce a prothrombotic/anti-fibrinolytic effect as apolipoprotein(a) resembles both plasminogen and plasmin but has no fibrinolytic activity, or may accelerate atherosclerosis because, like LDL, the Lp(a) particle is cholesterol-rich, or both.
|
20965889 |
2010 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A considerable body of data from genetic and epidemiological studies strongly support a causal relationship between high lipoprotein(a) [Lp(a)] levels, and the development of atherosclerosis and cardiovascular disease.
|
31350625 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic dyslipidemias can be identified in over 75% of CAD patients and include the atherosclerosis susceptibility trait (low density lipoprotein [LDL] pattern B), hyperapobetalipoproteinemia, lipoprotein (a), apo E isoforms, and lipoprotein susceptibility to oxidative damage.
|
7750049 |
1995 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified circulating miR-212 as a novel marker of atherosclerosis. miR-212 enhanced the estimation of atherosclerosis presence in combination with hemoglobin A1c, high-density lipoprotein cholesterol, and lipoprotein(a).
|
28557988 |
2017 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic vascular disease.
|
29912783 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, mice with inherited deficiency in LPA receptor signaling are protected from experimental atherosclerosis.
|
31533471 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice.
|
7897323 |
1994 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The apo(a) [apolipoprotein(a)] gene is responsible for variations in plasma lipoprotein(a), high levels of which are a risk factor for atherosclerosis and myocardial infarction.
|
14680477 |
2004 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease.
|
31061262 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increased concentrations of low-density-lipoprotein (LDL)-cholesterol (LDL-C) and lipoprotein a (Lp(a)) are scientifically accepted, independent risk factors for the development of atherosclerosis.
|
26789774 |
2016 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evaluating the Potential Association Between Lipoprotein(a) and Atherosclerosis (from the Mediators of Atherosclerosis Among South Asians Living in America Cohort).
|
30626499 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) and its position among other risk factors of atherosclerosis.
|
18198982 |
2008 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
FV Leiden was not a useful predictor (p=0.23) of the presence of clinically defined atherosclerosis (> or = 50% stenosis) in a logistic regression model adjusting for age, lipoprotein (a), total cholesterol, triglycerides, high density lipoprotein cholesterol, and fibrinogen.
|
9722025 |
1998 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elevated plasma levels of lipoprotein(a) [Lp(a)], referred to as lipoprotein(a)-hyperlipoproteinemia [Lp(a)-HLP], are an independent risk factor for atherosclerosis.
|
29096834 |
2017 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis.
|
2524837 |
1989 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transgenic mice expressing human apolipoprotein(a) develop aortic lesions resembling the early stages of human atherosclerosis after 3.5 months on a high fat diet.
|
8187213 |
1994 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Nontraditional cardiovascular risk factors such as lipoprotein(a) (Lp(a)), the genetic polymorphisms of apolipoprotein(a), apolipoprotein E (ApoE), and apolipoprotein B (ApoB) increase the prevalence of atherosclerosis in end-stage renal disease (ESRD) through quantitative and qualitative alterations.
|
31119518 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There is now significant evidence to support an independent causal role for lipoprotein(a) (Lp(a)) as a risk factor for atherosclerotic cardiovascular disease.
|
31783529 |
2019 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Many epidemiologic studies from Europe and North America have found that when plasma levels of lipoprotein (a) exceed 0.20 g/L, there is a significantly higher risk of coronary and cerebrovascular atherosclerosis.
|
2667728 |
1989 |